Overview

NCI Definition: An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation. (WHO, 2001) [1]

Significant Genes in Therapy-Related Acute Myeloid Leukemia

ABL1 +

ABL2 +

AFF1 +

ASXL1 +

BCOR +

BCR +

CBL +

CREBBP +

CRLF2 +

CSF1R +

DEK +

ELL +

EPOR +

ETV6 +

EZH2 +

FLT3 +

HIP1 +

HRAS +

IDH1 +

IDH2 +

IL7R +

JAK1 +

JAK2 +

JAK3 +

KIT +

KMT2A +

KRAS +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

NF1 +

NPM1 +

NRAS +

NUP214 +

PBX1 +

PDGFRB +

PRDM16 +

PTPN11 +

RIT1 +

RPN1 +

RUNX1 +

SF3B1 +

SH2B3 +

SRSF2 +

STAG2 +

TCF3 +

TP53 +

U2AF1 +

ZRSR2 +

Disease Details

Synonyms
Treatment-related Acute Myeloid Leukemia, Treatment Related Acute Myelogenous Leukemia, Treatment-Related AML, Treatment related AML, t-AML, Treatment Related Acute Myelocytic Leukemia, Treatment-Related Acute Myelocytic Leukemia, Treatment Related AML, Treatment Related Acute Myeloid Leukemia, Treatment related acute myeloid leukemia, Treatment-Related Acute Myelogenous Leukemia
Parent(s)
Therapy-Related Myeloid Neoplasm
OncoTree Name
Therapy-Related Acute Myeloid Leukemia
OncoTree Code
TAML

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.